Patents by Inventor Richard O. Hynes
Richard O. Hynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348605Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.Type: ApplicationFiled: February 28, 2023Publication date: November 2, 2023Applicants: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical ResearchInventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu J. Xie
-
Publication number: 20230295284Abstract: Provided herein are anti-FN-EIIIB nanobodies, conjugates thereof, and methods of using the nanobodies and conjugates thereof.Type: ApplicationFiled: January 31, 2023Publication date: September 21, 2023Applicant: Massachusetts Institute of TechnologyInventors: Richard O. Hynes, Karl Dane Wittrup, Noor Jailkhani, Noor Momin, Emi Lutz
-
Patent number: 11597769Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.Type: GrantFiled: January 25, 2019Date of Patent: March 7, 2023Assignees: Massachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical ResearchInventors: Richard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu Joy Xie
-
Publication number: 20190225693Abstract: Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.Type: ApplicationFiled: January 25, 2019Publication date: July 25, 2019Applicant: Massachusetts Institute of TechnologyInventors: Richard O. Hynes, Noor Jailkhani
-
Patent number: 10024860Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: GrantFiled: September 22, 2016Date of Patent: July 17, 2018Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20170343553Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: September 22, 2016Publication date: November 30, 2017Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20170051073Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: September 22, 2016Publication date: February 23, 2017Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Patent number: 9526800Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: GrantFiled: March 14, 2013Date of Patent: December 27, 2016Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Publication number: 20150086565Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
-
Patent number: 4487838Abstract: A crosslinking reagent consisting of a first functional group capable of forming a covalent derivative with a material of interest; a second functional group capable of forming an in situ bond to a neighboring material upon activation; a cleavable bond separating said first and second groups; and a radioactive marker to identify the neighboring material after cleavage of said bond, whereby in situ protein interactions can be studied.Type: GrantFiled: January 12, 1982Date of Patent: December 11, 1984Assignee: Massachusetts Institute of TechnologyInventors: Richard O. Hynes, Martin A. Schwartz